P4‐661: REPLICATION TRIAL TO CONFIRM REVERSAL OF COGNITIVE DECLINE WITH BRYOSTATIN FOR ADVANCED ALZHEIMER'S PATIENTS IN THE ABSENCE OF MEMANTINE | Zendy

Alkon Daniel L. | Zendy; Thompson Richard | Zendy; Wei Lee Jen | Zendy; Tuchman Alan | Zendy

Premium

P4‐661: REPLICATION TRIAL TO CONFIRM REVERSAL OF COGNITIVE DECLINE WITH BRYOSTATIN FOR ADVANCED ALZHEIMER'S PATIENTS IN THE ABSENCE OF MEMANTINE

Author(s) -

Alkon Daniel L.,

Thompson Richard,

Wei Lee Jen,

Tuchman Alan

Publication year - 2019

Publication title -

alzheimer's and dementia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.713

H-Index - 118

eISSN - 1552-5279

pISSN - 1552-5260

DOI - 10.1016/j.jalz.2019.09.027

Subject(s) - placebo , memantine , medicine , clinical endpoint , bryostatin 1 , donepezil , randomization , cognitive decline , randomized controlled trial , alzheimer's disease , psychology , dementia , disease , alternative medicine , receptor , pathology , activator (genetics)

synaptogenesis and prevent neuronal death, is being evaluated in a double-blind, placebo-controlled confirmatory trial as a treatment for advanced Alzheimer’s disease patients with a dose regimen of 20 μg of bryostatin compared to placebo. 108 subjects were randomized in a 1:1 treatment allocation. Subjects on Namenda (memantine) were excluded. Namenda was previously shown to block sustained cognitive improvement observed in a recently completed Phase II trial. (cf. Farlow et al., 2019 6).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research